30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma
Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants
Light Chain Deposition Disease (LCDD or MIDD) · Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) · Monoclonal Immunoglobulin Deposition Disease (MIDD)
Primary: Percentage of Participants Experiencing Progression Free Survival at 12 Months — 84 percentage of patients
Primary Systemic Amyloidosis · Light Chain Deposition Disease
Primary: Complete Hematologic Response — 16 participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants
Amyloidosis
Primary: Number of Participants With Disease Response — 20 Participants
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Multiple Myeloma
Primary: Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen — 77.2 percentage of participants
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic Response Rate — 55.9; 69.1 percentage of participants
Multiple Myeloma
Primary: Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer. — 0 participant response
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD) — 25; 1.3; 20; 30 mg
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Progression-Free Survival — 78; 52 percentage of participants
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Primary: Response Rate [Complete Response (CR) and Partial Response (PR)] — 0; 0; 0; 1 participants
Multiple Myeloma
Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Complete Response Rate — 7; 7 Participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Overall Response Rate (Complete and Partial) — 77.50 percentage of participants
Multiple Myeloma
Primary: Overall Response Rate — 95 percentage of participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment — 28; 16 participants
Multiple Myeloma
Primary: Objective Response Rate — 6; 16; 11; 10 Participants
Light Chain Deposition Disease · Primary Systemic Amyloidosis
Primary: Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR])…
Multiple Myeloma
Primary: Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate) — 4; 0; 3; 1 participants
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 31.87; NA Months — p=<0.0001